Indivior PLC (INDV)
NASDAQ: INDV · IEX Real-Time Price · USD
15.27
-0.48 (-3.05%)
At close: Jul 2, 2024, 4:00 PM
15.18
-0.09 (-0.59%)
After-hours: Jul 2, 2024, 6:19 PM EDT
Indivior Employees
Indivior had 1,164 employees as of December 31, 2023. The number of employees increased by 211 or 22.14% compared to the previous year.
Employees
1,164
Change (1Y)
211
Growth (1Y)
22.14%
Revenue / Employee
$965,636
Profits / Employee
$4,296
Market Cap
2.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1,164 | 211 | 22.14% |
| Dec 31, 2022 | 953 | 68 | 7.68% |
| Dec 31, 2021 | 885 | 66 | 8.06% |
| Dec 31, 2020 | 819 | -96 | -10.49% |
| Dec 31, 2018 | 915 | -108 | -10.56% |
| Dec 31, 2017 | 1,023 | 58 | 6.01% |
| Dec 31, 2016 | 965 | 80 | 9.04% |
| Dec 31, 2015 | 885 | 157 | 21.57% |
| Dec 31, 2014 | 728 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 19,000 |
| Patterson Companies | 7,600 |
| QuidelOrtho | 7,100 |
| Evolent Health | 4,700 |
| CONMED | 4,000 |
| UFP Technologies | 3,093 |
| Myriad Genetics | 2,700 |
| Certara | 1,391 |
INDV News
- 14 days ago - Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest - PRNewsWire
- 22 days ago - Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder - PRNewsWire
- 27 days ago - Opioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior) - GlobeNewsWire
- 5 weeks ago - Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance - PRNewsWire
- 2 months ago - Indivior Announces Q1 2024 Financial Results - PRNewsWire
- 4 months ago - Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone - PRNewsWire
- 4 months ago - Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation - PRNewsWire
- 4 months ago - Drugmaker Indivior consults on moving primary listing from London to US - Reuters